SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/11/23 Omega Therapeutics, Inc. 8-K:5,9 12/11/23 11:510K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 53K 2: EX-3.1 Articles of Incorporation/Organization or Bylaws HTML 294K 6: R1 Document and Entity Information HTML 51K 9: XML IDEA XML File -- Filing Summary XML 12K 7: XML XBRL Instance -- omga-20231211_htm XML 16K 8: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 4: EX-101.LAB XBRL Labels -- omga-20231211_lab XML 48K 5: EX-101.PRE XBRL Presentations -- omga-20231211_pre XML 37K 3: EX-101.SCH XBRL Schema -- omga-20231211 XSD 11K 10: JSON XBRL Instance as JSON Data -- MetaLinks 13± 20K 11: ZIP XBRL Zipped Folder -- 0000950170-23-069382-xbrl Zip 56K
8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM i 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): i December 11, 2023
__________________________________
i Omega Therapeutics, Inc.
(Exact Name of Registrant as specified in its charter)
__________________________________
i Delaware |
|
|
i 81-3247585
|
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
i 140 First Street, i Suite 501
i Cambridge, i Massachusetts i 02141
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: ( i 617) i 949-4360
N/A
(Former Name or Former Address, if Changed Since Last Report)
____________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbols |
|
Name of each exchange on which registered |
i Common Stock, $0.001 par value per share |
|
i OMGA |
|
i The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i ☐
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On December 7, 2023, the Board of Directors (the “Board”) of Omega Therapeutics, Inc., a Delaware corporation (the “Company”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day. Among other things, the amendments contained in the Amended and Restated Bylaws:
The Amended and Restated Bylaws also delete certain obsolete provisions and incorporate certain technical, modernizing, clarifying and conforming changes.
The foregoing description of the Amended and Restated Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
|
Description |
|
|
|
3.1 |
|
|
104 |
|
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
Date: December 11, 2023 |
Omega Therapeutics, Inc. |
||
|
|
|
|
|
By: |
/s/ Mahesh Karande |
|
|
|
||
|
|
President and Chief Executive Officer |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on / For Period end: | 12/11/23 | None on these Dates | ||
12/7/23 | ||||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/06/24 Omega Therapeutics, Inc. 10-Q 3/31/24 81:8.5M Donnelley … Solutions/FA 3/28/24 Omega Therapeutics, Inc. 10-K 12/31/23 94:15M Donnelley … Solutions/FA |